Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 152-156 , March 2010

Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone

  • Orazio Caffo, M.D.

      Affiliations

    • Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-0461-903451; fax: +39-461-903364
    • ,
  • Teodoro Sava, M.D.

      Affiliations

    • Medical Oncology Department, University of Verona, Verona, Italy
    • ,
  • Evi Comploj, M.D.

      Affiliations

    • Urology Department, San Maurizio Hospital, Bolzano, Italy
    • ,
  • Maria Anna Giampaolo, M.D.

      Affiliations

    • Oncology Department, Civil Hospital, Anagni, Italy
    • ,
  • Romana Segati, M.D.

      Affiliations

    • Oncology Department, Civil Hospital, Feltre, Italy
    • ,
  • Francesco Valduga, M.D.

      Affiliations

    • Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
    • ,
  • Gianluigi Cetto, M.D.

      Affiliations

    • Medical Oncology Department, University of Verona, Verona, Italy
    • ,
  • Enzo Galligioni, M.D.

      Affiliations

    • Medical Oncology Department, Santa Chiara Hospital, Trento, Italy

Received 1 June 2008 ,Revised 28 July 2008 ,Accepted 29 July 2008.

References 

  1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  3. Sartor O, Petrylak DP, Witjes JA, et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the Phase III satraplatin and prednisone against refractory cancer (SPARC) trial. Proc Am Soc Clin Oncol. 2008;26:abstr 5003
  4. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. Eur Urol. 2008;54:1089–1094
  5. Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008;101:308–312
  6. Ross RW, Beer TM, Jacobus S, et al. A Phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112:521–526
  7. Hudes G, Einhorn L, Ross E, et al. Vinblastine vs. vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial. J Clin Oncol. 1999;17:3160–3166
  8. Berry WR, Hathorn JW, Dakhil SR, et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer. 2004;3:104–111
  9. Eymard JC, Priou F, Zannetti A, et al. Randomized Phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol. 2007;18:1064–1070
  10. Caffo O, Sava T, Comploj E, et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: Results of a multicenter, randomized Phase II trial. BJU Int. 2008;102:1080–1085
  11. Montgomery RB, Nelson PS, Lin D, et al. Diethylstilbestrol and docetaxel: A Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer. 2007;110:996–1002
  12. Fizazi K, Le MA, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: A meta-analysis of individual patient data. Lancet Oncol. 2007;8:994–1000
  13. Heidenreich A, Aus G, Bolla M. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  14. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461–3467
  15. Therasse P. Measuring the clinical response (What does it mean?). Eur J Cancer. 2002;38:1817–1823
  16. Oudard S, Legrier ME, Boye K, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003;169:1729–1734
  17. Petrylak DP, Macarthur R, O'Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol. 1999;26(5 Suppl 17):28–33
  18. Sitka CM, Ledakis P, Lynch J, et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol. 2001;28(4 Suppl 15):16–21
  19. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780 (Cancer and Leukemia Group B). J Clin Oncol. 2001;19:2509–2516
  20. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002;94:1457–1465
  21. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized Phase II study of two schedules of docetaxel, estramustine, and prednisone vs. mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:3343–3351

PII: S1078-1439(08)00192-0

doi: 10.1016/j.urolonc.2008.07.033

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 152-156 , March 2010

Article Tools